

## Supplementary material

### *Search Strategies*

Web of Science

(Sodium-Glucose Transporter 2 Inhibitors OR SGLT2 OR SGLT-2 OR SGLT 2 OR tofogliflozin OR empagliflozin OR dapagliflozin OR canagliflozin OR sotagliflozin OR luseogliflozin OR ipragliflozin OR remogliflozin OR sergliflozin OR ertugliflozin) AND (ketoacidosis OR euglycemic ketoacidosis OR diabetic ketoacidosis) AND (COVID19 OR SARS-CoV-2 OR Coronavirus)

PubMed:

("Sodium-Glucose Transporter 2 Inhibitors"[Mesh] OR "SGLT2"[tw] OR "SGLT-2"[tw] OR "SGLT 2\*"[tw] OR "tofogliflozin"[tw] OR "empagliflozin"[tw] OR "dapagliflozin"[tw] OR "canagliflozin"[tw] OR "sotagliflozin"[tw] OR "luseogliflozin"[tw] OR "ipragliflozin"[tw] OR "remogliflozin"[tw] OR "sergliflozin"[tw] OR "ertugliflozin"[tw]) AND ("Diabetic Ketoacidosis"[Mesh] OR "ketoacidosis"[tw] OR "euglycemic ketoacidosis\*"[tw]) AND ("COVID-19"[Mesh] OR "SARS-CoV-2"[Mesh] OR "Coronavirus"[Mesh])

Scopus:

("Sodium-Glucose cotransporter 2 Inhibitors" OR SGLT2 OR SGLT-2 OR "SGLT 2" OR tofogliflozin OR empagliflozin OR dapagliflozin OR

canagliflozin OR sotagliflozin OR luseogliflozin OR ipragliflozin OR  
remogliflozin OR sergliflozin OR ertugliflozin) AND (ketoacidosis OR  
“euglycemic ketoacidosis” OR “diabetic ketoacidosis”) AND (COVID-19 OR  
SARS-CoV-2 OR Coronavirus):

Google Scholar:

COVID-19 + sodium-glucose cotransporter 2 inhibitors + diabetes mellitus +  
euglycemic diabetic ketoacidosis.

**Supplementary Table 1 Quality Assessment using CARE guidelines**

Ref.	Keywords	Abstract	Introduction	Patient Info	Clinical Findings	Timeline	Diagnostic Assessment	Therapeutic Intervention	Follow-up and Outcomes	Discussion	Patient Perspective	Informed Consent
Oriot <i>et al</i> <sup>[29]</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Dass <i>et al</i> <sup>[14]</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Vitale <i>et al</i> <sup>[15]</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Batista <i>et al</i> <sup>[16]</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Philippe <i>et al</i> <sup>[17]</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes
Morrison <i>et al</i> <sup>[18]</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes
Fang <i>et al</i> <sup>[19]</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Yii ESS <i>et al</i> <sup>[28]</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes